Aslan Current Assets vs Shareholders Equity Analysis

ASLN Stock

USD 0.50 0.04 7.41%

Trend analysis of Aslan Pharmaceuticals Ltd balance sheet accounts such as Short Long Term Debt Total of 19.9 M, Other Current Liabilities of 2 M or Total Current Liabilities of 8.8 M provides information on Aslan Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Aslan Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Aslan Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Total Assets Net Tangible Assets

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About Aslan Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Aslan Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Aslan Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Aslan Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Aslan currently owns. An asset can also be divided into two categories, current and non-current.

Aslan Pharmaceuticals Balance Sheet Chart

Aslan Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Aslan Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, Aslan Pharmaceuticals' Other Current Assets are very stable compared to the past year. As of the 16th of April 2024, Property Plant And Equipment Gross is likely to grow to about 375 K, while Short and Long Term Debt Total is likely to drop about 19.9 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Aslan Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aslan Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Aslan Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aslan Pharmaceuticals Ltd are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Aslan Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aslan Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

As of the 16th of April 2024, Selling General Administrative is likely to drop to about 9.5 M. In addition to that, Tax Provision is likely to drop to about 141.5 K

Aslan Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Short Term Debt
Total Assets		0.63	0.18	0.46	0.87	0.39	0.3	-0.83	-0.51	0.51	0.98	0.24	0.31	0.11	-0.06	0.98	0.63	0.66	-0.22	0.63	0.7	0.02	0.29	-0.64	0.97	-0.71
Short Long Term Debt Total	0.63		0.3	0.87	0.39	-0.23	0.33	-0.23	-0.89	0.81	0.62	-0.02	0.61	-0.02	-0.19	0.62	0.8	0.93	-0.06	0.92	0.95	0.36	0.37	-0.43	0.65	-0.5
Other Current Liab	0.18	0.3		0.44	0.12	0.11	0.5	0.06	-0.46	0.55	0.1	0.32	0.24	0.55	0.06	0.1	0.49	0.44	-0.18	0.16	0.4	0.04	0.54	-0.56	0.11	-0.53
Total Current Liabilities	0.46	0.87	0.44		0.27	-0.07	0.34	-0.06	-0.81	0.95	0.43	0.09	0.78	-0.01	-0.21	0.43	0.75	0.83	-0.2	0.76	0.83	0.28	0.37	-0.45	0.45	-0.46
Total Stockholder Equity	0.87	0.39	0.12	0.27		0.63	0.42	-0.85	-0.29	0.34	0.84	0.33	0.11	0.18	-0.33	0.84	0.62	0.48	-0.55	0.31	0.54	-0.43	0.41	-0.56	0.83	-0.61
Net Tangible Assets	0.39	-0.23	0.11	-0.07	0.63		0.28	-0.63	0.19	0.02	0.41	0.05	-0.09	-0.08	-0.12	0.41	0.14	0.0	-0.55	-0.22	-0.04	-0.59	0.27	-0.42	0.39	-0.38
Property Plant And Equipment Net	0.3	0.33	0.5	0.34	0.42	0.28		-0.15	-0.47	0.23	0.29	0.06	0.04	0.4	-0.28	0.29	0.72	0.41	-0.61	0.07	0.46	-0.43	0.99	-0.69	0.29	-0.65
Net Debt	-0.83	-0.23	0.06	-0.06	-0.85	-0.63	-0.15		0.02	-0.13	-0.86	-0.06	-0.11	0.01	-0.08	-0.86	-0.3	-0.28	0.12	-0.22	-0.31	0.13	-0.12	0.46	-0.85	0.51
Retained Earnings	-0.51	-0.89	-0.46	-0.81	-0.29	0.19	-0.47	0.02		-0.75	-0.49	-0.03	-0.36	-0.03	0.23	-0.49	-0.85	-0.92	0.23	-0.84	-0.92	-0.21	-0.52	0.54	-0.51	0.6
Accounts Payable	0.51	0.81	0.55	0.95	0.34	0.02	0.23	-0.13	-0.75		0.46	0.18	0.78	0.02	-0.25	0.46	0.68	0.8	-0.21	0.75	0.8	0.24	0.27	-0.39	0.48	-0.41
Cash	0.98	0.62	0.1	0.43	0.84	0.41	0.29	-0.86	-0.49	0.46		0.03	0.31	-0.05	-0.03	1.0	0.59	0.64	-0.16	0.65	0.67	0.06	0.29	-0.6	1.0	-0.67
Non Current Assets Total	0.24	-0.02	0.32	0.09	0.33	0.05	0.06	-0.06	-0.03	0.18	0.03		-0.06	0.79	-0.09	0.03	0.22	0.04	-0.27	-0.14	0.11	-0.23	0.06	-0.28	0.02	-0.25
Non Currrent Assets Other	0.31	0.61	0.24	0.78	0.11	-0.09	0.04	-0.11	-0.36	0.78	0.31	-0.06		-0.11	-0.07	0.31	0.28	0.42	0.08	0.55	0.44	0.43	0.03	-0.1	0.33	-0.07
Other Assets	0.11	-0.02	0.55	-0.01	0.18	-0.08	0.4	0.01	-0.03	0.02	-0.05	0.79	-0.11		0.11	-0.05	0.26	0.0	-0.13	-0.27	0.07	-0.14	0.39	-0.41	-0.06	-0.37
Long Term Debt	-0.06	-0.19	0.06	-0.21	-0.33	-0.12	-0.28	-0.08	0.23	-0.25	-0.03	-0.09	-0.07	0.11		-0.03	-0.32	-0.18	0.79	-0.17	-0.28	0.67	-0.28	-0.24	-0.04	-0.21
Cash And Short Term Investments	0.98	0.62	0.1	0.43	0.84	0.41	0.29	-0.86	-0.49	0.46	1.0	0.03	0.31	-0.05	-0.03		0.59	0.64	-0.16	0.65	0.67	0.06	0.29	-0.6	1.0	-0.67
Common Stock Total Equity	0.63	0.8	0.49	0.75	0.62	0.14	0.72	-0.3	-0.85	0.68	0.59	0.22	0.28	0.26	-0.32	0.59		0.9	-0.49	0.6	0.92	-0.13	0.76	-0.74	0.6	-0.78
Common Stock Shares Outstanding	0.66	0.93	0.44	0.83	0.48	0.0	0.41	-0.28	-0.92	0.8	0.64	0.04	0.42	0.0	-0.18	0.64	0.9		-0.21	0.85	0.98	0.2	0.47	-0.59	0.67	-0.68
Non Current Liabilities Total	-0.22	-0.06	-0.18	-0.2	-0.55	-0.55	-0.61	0.12	0.23	-0.21	-0.16	-0.27	0.08	-0.13	0.79	-0.16	-0.49	-0.21		0.04	-0.27	0.87	-0.61	0.27	-0.16	0.25
Other Current Assets	0.63	0.92	0.16	0.76	0.31	-0.22	0.07	-0.22	-0.84	0.75	0.65	-0.14	0.55	-0.27	-0.17	0.65	0.6	0.85	0.04		0.85	0.44	0.11	-0.26	0.67	-0.35
Other Stockholder Equity	0.7	0.95	0.4	0.83	0.54	-0.04	0.46	-0.31	-0.92	0.8	0.67	0.11	0.44	0.07	-0.28	0.67	0.92	0.98	-0.27	0.85		0.14	0.51	-0.57	0.69	-0.65
Total Liab	0.02	0.36	0.04	0.28	-0.43	-0.59	-0.43	0.13	-0.21	0.24	0.06	-0.23	0.43	-0.14	0.67	0.06	-0.13	0.2	0.87	0.44	0.14		-0.41	0.03	0.07	0.01
Property Plant And Equipment Gross	0.29	0.37	0.54	0.37	0.41	0.27	0.99	-0.12	-0.52	0.27	0.29	0.06	0.03	0.39	-0.28	0.29	0.76	0.47	-0.61	0.11	0.51	-0.41		-0.7	0.28	-0.67
Short Long Term Debt	-0.64	-0.43	-0.56	-0.45	-0.56	-0.42	-0.69	0.46	0.54	-0.39	-0.6	-0.28	-0.1	-0.41	-0.24	-0.6	-0.74	-0.59	0.27	-0.26	-0.57	0.03	-0.7		-0.59	0.99
Total Current Assets	0.97	0.65	0.11	0.45	0.83	0.39	0.29	-0.85	-0.51	0.48	1.0	0.02	0.33	-0.06	-0.04	1.0	0.6	0.67	-0.16	0.67	0.69	0.07	0.28	-0.59		-0.67
Short Term Debt	-0.71	-0.5	-0.53	-0.46	-0.61	-0.38	-0.65	0.51	0.6	-0.41	-0.67	-0.25	-0.07	-0.37	-0.21	-0.67	-0.78	-0.68	0.25	-0.35	-0.65	0.01	-0.67	0.99	-0.67

Click cells to compare fundamentals

Aslan Pharmaceuticals Account Relationship Matchups

Aslan Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	23.3M	16.1M	94.5M	61.2M	24.6M	45.1M
Short Long Term Debt Total	18.4M	19.3M	31.1M	37.6M	26.8M	19.9M
Other Current Liab	3.2M	267K	223.4K	2.4M	3.2M	2.0M
Total Current Liabilities	5.4M	10.7M	6.4M	23.2M	13.1M	8.8M
Total Stockholder Equity	(1.7M)	(10.5M)	57.3M	8.4M	(13.3M)	(12.6M)
Other Liab	4.8M	8.9M	13.4M	112.0K	128.8K	122.3K
Net Tangible Assets	(50.3M)	(10.5M)	57.3M	8.4M	7.5M	7.1M
Property Plant And Equipment Net	766.2K	475.9K	232.7K	292.7K	259.2K	366.0K
Net Debt	(3.8M)	4.9M	(59.1M)	(19.3M)	5.6M	5.9M
Retained Earnings	(179.5M)	(195.7M)	(227.0M)	(278.4M)	(321.1M)	(305.0M)
Accounts Payable	1.9M	2.3M	3.1M	12.8M	7.9M	4.4M
Cash	22.2M	14.3M	90.2M	56.9M	21.3M	40.5M
Non Current Assets Total	1.1M	579.4K	737.4K	307.2K	496.5K	471.7K
Non Currrent Assets Other	108.1K	103.3K	10.0K	8.6M	1.7K	1.6K
Other Assets	7.1M	5.3M	103.3K	1.0	1.15	1.09
Long Term Debt	17.6M	15.2M	30.9M	29.7M	26.7M	25.4M
Cash And Short Term Investments	22.2M	14.3M	90.2M	56.9M	21.3M	40.5M
Common Stock Total Equity	43.8M	51.6M	61.4M	61.8M	71.1M	40.0M
Common Stock Shares Outstanding	6.5M	7.7M	13.0M	13.9M	16.4M	8.4M
Liabilities And Stockholders Equity	23.3M	16.1M	94.5M	61.2M	24.6M	45.1M
Non Current Liabilities Total	18.6M	15.6M	30.9M	29.7M	24.8M	19.4M
Other Current Assets	68.9K	649.1K	3.6M	4.0M	2.7M	2.8M
Other Stockholder Equity	116.5M	123.6M	221.5M	223.9M	219.8M	127.5M
Total Liab	24.0M	26.2M	37.2M	52.8M	37.9M	35.5M
Property Plant And Equipment Gross	766.2K	475.9K	232.7K	292.7K	336.7K	375.0K
Total Current Assets	22.3M	15.5M	93.8M	60.9M	24.1M	41.9M
Short Term Debt	264.5K	3.8M	199.1K	8.0M	2.0M	3.5M
Intangible Assets	23.1M	2.8K	160.0	5.8M	6.7M	4.8M
Common Stock	51.6M	61.4M	61.8M	63.0M	63.9M	48.9M
Property Plant Equipment	23.0M	475.9K	232.7K	292.7K	263.5K	250.3K
Capital Lease Obligations	755.4K	552.8K	199.1K	215.7K	248.0K	236.9K
Non Current Liabilities Other	161.8K	289.6K	447.2K	112.0K	128.8K	185.3K
Net Invested Capital	16.0M	8.2M	88.2M	45.8M	52.6M	45.4M
Net Working Capital	16.9M	4.8M	87.4M	37.7M	43.4M	39.0M

Pair Trading with Aslan Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Aslan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aslan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aslan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aslan Pharmaceuticals Ltd to buy it.

The correlation of Aslan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aslan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aslan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Aslan Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aslan Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aslan Pharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aslan Pharmaceuticals Ltd Stock:

How To Invest In Aslan

Details

Is Aslan Stock a good investment?

Details

What is Aslan Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Aslan Stock analysis

When running Aslan Pharmaceuticals' price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance

Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.75)

Revenue Per Share

0.746

Return On Assets

(0.64)

Return On Equity

(4.27)

The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aslan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aslan Current Assets vs Shareholders Equity Analysis

About Aslan Balance Sheet Analysis

Aslan Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Aslan Pharmaceuticals fundamental ratios Correlations

Aslan Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aslan Pharmaceuticals fundamental ratios Accounts

Pair Trading with Aslan Pharmaceuticals

Complementary Tools for Aslan Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Short Term Debt	+ 0.99	Short Long Term Debt
Cash	+ 0.98	Total Assets

Other Stockholder Equity	- 0.92	Retained Earnings
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Retained Earnings	- 0.89	Short Long Term Debt Total
Cash And Short Term Investments	- 0.86	Net Debt
Cash	- 0.86	Net Debt
Common Stock Total Equity	- 0.85	Retained Earnings